We use cookies to enhance your browsing experience and analyze site traffic. By continuing to use this site, you agree to our cookie policy. Privacy Policy
The 2026 Biophysics Congress was recently held in Hainan, where Clickmab presented its proprietary Click.mAb. AI antibody R&D platform and shared its technical explorations in epitope-specific de novo design, affinity maturation, and humanization. During the congress, Zhang Hong, academician of the Chinese Academy of Sciences and president of the Chinese Biophysical Society, visited Clickmab's booth for an in-depth exchange.
The 2026 Biophysics Congress took place at the Boao Forum for Asia International Conference Center in Hainan. Under the theme "Biophysics and Human Health," researchers in life sciences, biophysics, and AI discussed advances and applications in biomedical research.
Clickmab presented its proprietary Click.mAb. platform and work on epitope-specific de novo antibody design, affinity optimization, and humanization.
Zhang Hong, an academician of the Chinese Academy of Sciences, president of the Chinese Biophysical Society, and chair of the congress organizing committee, visited the booth to discuss AI antibody design and its applications with the team.
Academician Zhang Hong (2nd from left) visits Clickmab's booth
Traditional antibody discovery typically relies on experimental strategies such as animal immunization and phage display, obtaining candidate molecules by constructing antibody libraries and conducting large-scale screening. However, for certain targets with low immunogenicity, cryptic epitopes, or conformation-dependent structures, traditional methods often face challenges such as difficulty in candidate acquisition and insufficient epitope control.
Systemic Blind Spots in Traditional Methods
In the "AI Biology: New Paradigms and Applications" forum, Dr. Tianyuan Wang, CEO of Clickmab, delivered a keynote titled "Epitope-Specific AI De Novo Antibody Design for Antibody Drug R&D: Technical Principles, Current Applications, and Breakthrough Strategies."
Dr. Tianyuan Wang presenting on-site
The talk explored how generative AI can combine antigen structures and epitope information to design candidates for specific binding sites. It also showed how computational design and experimental validation can work together in antibody discovery.
This approach connects sequence generation, structural assessment, and laboratory testing in an iterative design-and-validation workflow.
Clickmab's Precise Control over Epitopes
Clickmab demonstrated how Click.mAb. combines generative AI, structural analysis, and research agents across the antibody discovery workflow. Applications explored to date include:
· Epitope-specific de novo antibody design
· Affinity maturation
· CDR diversification
· mAb and nanobody humanization
· Developability assessment
· Structure prediction and related analysis
The platform helps teams connect computational results with experimental work and candidate selection.
The team met researchers from universities, research institutions, and industry to discuss opportunities for AI in biophysics and drug discovery.
Clickmab will continue developing AI tools alongside experimental workflows to support antibody design and engineering. We welcome researchers interested in applying these approaches to their own projects.
Clickmab is dedicated to empowering antibody discovery through generative AI and welcomes partners across the ecosystem.